Engineering Macrophages for Cancer Immunotherapy and Drug Delivery
Abstract
Macrophages play an important role in cancer development and metastasis. Proinflammatory M1 macrophages can phagocytose tumor cells, while anti‐inflammatory M2 macrophages such as tumor‐associated macrophages (TAMs) promote tumor growth and invasion. Modulating the tumor immune microenvironment through engineering macrophages is efficacious in tumor therapy. M1 macrophages target cancerous cells and, therefore, can be used as drug carriers for tumor therapy. Herein, the strategies to engineer macrophages for cancer immunotherapy, such as inhibition of macrophage recruitment, depletion of TAMs, reprograming of TAMs, and blocking of the CD47‐SIRPα pathway, are discussed. Further, the recent advances in drug delivery using M1 macrophages, macrophage‐derived exosomes, and macrophage‐membrane‐coated nanoparticles are elaborated. Overall, there is still significant room for development in macrophage‐mediated immune modulation and macrophage‐mediated drug delivery, which will further enhance current tumor therapies against various malignant solid tumors, including drug‐resistant tumors and metastatic tumors.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Drug delivery systems based on different cell membrane coatings can endow brain targeting abilities.
“many drug delivery systems based on different cells’ membrane coating, such as red cell membrane, brain tumor cell membrane, immune cell membrane, and so on, could endow the brain targeting abilities”
From The blood–brain barrier: Structure, regulation and drug delivery (2023) · cites this paper as [192]
Cites
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002 · see citing works
Protective and pathogenic functions of macrophage subsets
Murray, P. J., & Wynn, T. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3073 · Cited by 5,269 · see citing works
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218 · see citing works
Macrophage plasticity, polarization, and function in health and disease
Shapouri‐Moghaddam, A., Mohammadian, S., Vazini, H., Taghadosi, M., Esmaeili, S., Mardani, F., Seifi, B., Mohammadi, A., Afshari, J. T., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26429 · Cited by 4,930 · see citing works
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586 · see citing works
Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752 · see citing works
Tan, H.-Y., Wang, N., Li, S., Hong, M., Wang, X., & Feng, Y. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/2795090 · Cited by 657 · see citing works
Recent Advances in Cell Membrane–Camouflaged Nanoparticles for Cancer Phototherapy
Zhen, X., Cheng, P., & Pu, K. (2019) · Small · doi:10.1002/smll.201804105 · Cited by 483 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Targeting Ferroptosis as a Vulnerability in Cancer
Lei, G., Zhuang, L., & Gan, B. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00459-0 · Cited by 2,252 · see citing works
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906 · see citing works
Self-citationNanoparticles for Cancer Therapy: Current Progress and Challenges
Gavas, S., Quazi, S., & Karpiński, T. M. (2021) · Nanoscale Research Letters · doi:10.1186/s11671-021-03628-6 · Cited by 1,069 · see citing works
Combination strategies to maximize the benefits of cancer immunotherapy
Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01164-5 · Cited by 654 · see citing works
Beygi, M., Oroojalian, F., Hosseini, S. S., Mokhtarzadeh, A., Kesharwani, P., & Sahebkar, A. (2023) · Progress in Materials Science · doi:10.1016/j.pmatsci.2023.101209 · Cited by 32 · see citing works
Retracted
- Authors
- Xia, Y., Rao, L., Yao, H., Wang, Z., Ning, P., & Chen, X.
- Affiliations
- Xidian University (CN)
- National Institutes of Health (US)
- Corresponding author
- Wang, Zhongliang
- Ning, Pengbo
- Chen, Xiaoyuan
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2020-08-28
- Volume
- 32
- Issue
- 40
- Pages
- e2002054-e2002054
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W3082328907
- Cited by
- 949
- References
- 8
- Citations by year
- 2026: 98 · 2025: 167 · 2024: 207 · 2023: 215 · 2022: 181 · 2021: 76 · 2020: 5
- FWCI
- 11.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Advanced Materials (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Basic Research Program of China (2017YFC1309100, 2017YFA0205200)
- National Natural Science Foundation of China (81671753, 91959124, 81227901, 21804104)
- Fundamental Research Funds for the Central Universities (JB191211, JB191207, JB191208)
- National Institute of Biomedical Imaging and Bioengineering
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Cancer Research and Treatments
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- macrophage engineering, cancer immunotherapy, tumor-associated macrophages, M1 macrophages, M2 macrophages, tumor immune microenvironment, TAM depletion, TAM reprogramming, macrophage-derived exosomes, macrophage membrane-coated nanoparticles, drug-resistant cancer, metastatic cancer
- MeSH terms
- Animals, Humans, Immunotherapy, Macrophages, Neoplasms, Drug Delivery Systems, Cell Engineering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
